Fluoxetine affords robust neuroprotection in the postischemic brain via its anti-inflammatory effect

Journal of Neuroscience Research

Volumn 87, Issue 4, 2009, Pages 1037-1045

  Lim, Chae Moon ^a   Kim, Seung Woo ^a   Park, Ju Young ^b   Kim, Chaekyun ^a   Yoon, Sung Hwa ^b   Lee, Ja Kyeong ^a  

^a Inha University School of Medicine   (South Korea)

^b Ajou University   (South Korea)

Author keywords

Fluoxetine; Inflammation; MCAO; Neuroprotection

Indexed keywords

FLUOXETINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIPOPOLYSACCHARIDE; BIOLOGICAL MARKER; NEUROPROTECTIVE AGENT; NONSTEROID ANTIINFLAMMATORY AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BRAIN INFARCTION SIZE; BRAIN INJURY; BRAIN ISCHEMIA; CELL ACTIVATION; CELL CULTURE; CONTROLLED STUDY; DOSE RESPONSE; MALE; MICROGLIA; MIDDLE CEREBRAL ARTERY OCCLUSION; MOTOR DYSFUNCTION; NERVE CELL NECROSIS; NEUROLOGIC DISEASE; NEUROPROTECTION; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RAT; ANIMAL; CEREBRAL ARTERY DISEASE; COGNITIVE DEFECT; DRUG ANTAGONISM; DRUG EFFECT; IMMUNOLOGY; METABOLISM; MOTOR ACTIVITY; NEUTROPHIL; PATHOPHYSIOLOGY; PHYSIOLOGY; SPRAGUE DAWLEY RAT;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BIOLOGICAL MARKERS; CELLS, CULTURED; COGNITION DISORDERS; DOSE-RESPONSE RELATIONSHIP, DRUG; FLUOXETINE; INFARCTION, MIDDLE CEREBRAL ARTERY; LIPOPOLYSACCHARIDES; MALE; MICROGLIA; MOTOR ACTIVITY; NEUROPROTECTIVE AGENTS; NEUTROPHILS; NF-KAPPA B; RATS; RATS, SPRAGUE-DAWLEY;

EID: 63849303038     PISSN: 03604012     EISSN: 10974547     Source Type: Journal    
DOI: 10.1002/jnr.21899     Document Type: Article

References (31)

1. Abdel-Salam OM, Baiuomy AR, Arbid MS. 2004. Studies on the antiinflammatory effect of fluoxetine in the rat. Pharmacol Res 49:119-131.
2. Battaglino R, Fu J, Späte U, Ersoy U, Joe M, Sedaghat L, Stashenko P. 2004. Serotonin regulates osteoclast differentiation through its transporter. J Bone Miner Res 19:1420-1431.
3. Bianchi M, Sacerdote P, Panerai AE. 1994. Fluoxetine reduces inflammatory edema in the rat: involvement of the pituitary-adrenal axis. Eur J Pharmacol 263:81-4.
4. Chen J, Li Y, Wang L, Zhang Z, Lu D, Lu M, Chopp M. 2007. Therapeutic benefit of intravenous administration of bone marrow stromal cells after cerebral ischemia in rats. Stroke 32:1005-1011.
5. Coppell AL, Pei Q, Zetterstrom TS. 2003. Bi-phasic change in BDNF gene expression following antidepressant drug treatment. Neuropharmacology 44:903-910.
6. Dam M, Tonin P, De Boni A, Pizzolato G, Casson S, Ermani M, Freo U, Piron L, Battistin L. 1996. Effects of fluoxetine and maprotiline on functional recovery in poststroke hemiplegic patients undergoing rehabilitation therapy. Stroke 27:1211-1214.
7. Dirnagl U, Iadecola C, Moskowitz MA. 1999. Pathobiology of ischaemic stroke: an integrated view. Trends Neurosci 22:391-397.
8. Gainotti G, Antonucci G, Marra C, Paolucci S. 2001. Relation between depression after stroke, antidepressant therapy, and functional recovery. J Neurol Neurosurg Psychiatry 71:258-261.
9. Graham SH, Chen J. 2001. Programmed cell death in cerebral ischemia. J Cereb Blood Flow Metab 21:99-109.
10. Ha E, Jung KH, Choe BK, Bae JH, Shin DH, Yim SV, Baik HH. 2006. Fluoxetine increases the nitric oxide production via nuclear factor kappa B-mediated pathway in BV2 murine microglial cells. Neurosci Lett 397:185-189.
11. Horsfield SA, Rosse RB, Tomasino V, Schwartz BL, Mastropaolo J, Deutsch SI. 2002. Fluoxetine's effects on cognitive performance in patients with traumatic brain injury. Int J Psychiatry Med 32:337-344.
12. Imai Y, Ibata I, Ito D, Obsawa K, Kohsaka S. 1996. A novel gene ibal in the major histocompatibility complex class III region encoding an EF hand protein expressed in a monocytic lineage. Biochem Biophys Res Commun 224:855-862.
13. Jolkkonen J, Puurunen K, Rantakomi S, Sirvio J, Haapalinna A, Sivenius J. 2000. Effect of fluoxetine on sensorimotor and spatial learning deficits following focal cerebral ischemia in rats. Restor Neurol Neurosci 17:211-216.
14. Kim JB, Sig Choi J, Yu YM, Nam K, Piao CS, Kim SW, Lee MH, Han PL, Park JS, Lee JK. 2006. HMGB1, a novel cytokine-like mediator linking acute neuronal death and delayed neuroinflammation in the postischemic brain. J Neurosci 26:6413-6421.
15. Kim JB, Piao CS, Lee KW, Han PL, Ahn JI, Lee YS, Lee JK. 2004. Delayed genomic responses to transient middle cerebral artery occlusion in the rat. J Neurochem 89:1271-1282.
16. Kim DH, Li H, Yoo KY, Lee BH, Hwang IK, Won MH. 2007. Effects of fluoxetine on ischemic cells and expressions in BDNF and some antioxidants in the gerbil hippocampal CA1 region induced by transient ischemia. Exp Neurol 204:748-758.
17. Kirino T. Delayed neuronal death. 2000. Neuropathology 20:S95-S97.
18. Kolla N, Wei Z, Richardson JS, Li XM. 2005. Amitriptyline and fluoxetine protect PC12 cells from cell death induced by hydrogen peroxide. J Psychiatry Neurosci 30:196-201.
19. Lalancette-Hébert M, Gowing G, Simard A, Weng YC, Kriz J. 2007. Selective ablation of proliferating microglial cells exacerbates ischemic injury in the brain. J Neurosci 27:2596-2605.
20. Lipton P. 1999. Ischemic cell death in brain neurons. Physiol Rev 79:1431-1568.
21. Nibuya M, Nestler EJ, Duman RS. 1996. Chronic antidepressant administration increases the expression of cAMP response element binding protein (CREB) in rat hippocampus. J Neurosci 16:2365-2372.
22. Pariente J, Loubinoux I, Carel C, Albucher JF, Leger A, Manelfe C, Rascol O, Chollet F. 2001. Fluoxetine modulates motor performance and cerebral activation of patients recovering from stroke. Ann Neurol 50:718-729.
23. Perkins ND. 2007. Integrating cell-signalling pathways with NF-kappaB and IKK function. Nat Rev Mol Cell Biol 8:49-62.
24. Post A, Crochemore C, Uhr M, Holsboer F, Behl C. 2000. Differential induction of NF-kappaB activity and neural cell death by antidepressants in vitro. Eur J Neurosci 12:4331-4337.
25. Robertson DW, Krushinski JH, Fuller RW, Leander JD. 1998. Absolute configuration and pharmacological active of the optical isomers of fluoxetine, a selective serotonin-uptake inhibitor. J Med Chem 31: 1412-1417.
26. Roumestan C, Michel A, Bichon F. 2007. Anti-inflammatory properties of desipramine and fluoxetine. Respir Res 8:35-45.
27. Wiart L, Petit H, Joseph PA, Mazaux JM, Barat M. 2000. Fluoxetine in early poststroke depression: a double-blind placebo-controlled study. Stroke 31:1829-1832.
28. Windle V, Corbett D. 2005. Fluoxetine and recovery of motor function after focal ischemia in rats. Brain Res 1044:25-32.
29. Yu YM, Kim JB, Lee KW, Kim SY, Han PL, Lee JK. 2005. Inhibition of the cerebral ischemic injury by ethyl pyruvate with a wide therapeutic window. Stroke 36:2238-2243.
30. Zafir A, Banu N. 2007. Antioxidant potential of fluoxetine in comparison to Curcuma longa in restraint-stressed rats. Eur J Pharmacol 572:23-31.
31. Zhao CS, Puurunen K, Schallertb T, Siveniusd J, Jolkkonen J. 2005. Behavioral and histological effects of chronic antipsychotic and antidepressant drug treatment in aged rats with focal ischemic brain injury. Behav Brain Res 158:211-220.